Ovarian Cancer Screening: Evidence-Based Recommendations
Ovarian cancer screening is NOT recommended for average-risk women, as randomized controlled trials have definitively shown no mortality benefit while causing substantial harms from false-positive results and unnecessary surgeries. 1, 2
Average-Risk Women: Do Not Screen
The evidence against screening in average-risk asymptomatic women is conclusive:
Mortality Evidence
The PLCO (Prostate, Lung, Colorectal, and Ovarian) Cancer Screening Trial—the definitive study involving 78,216 women followed for up to 13 years—found no reduction in ovarian cancer deaths with annual CA-125 testing and transvaginal ultrasonography (118 deaths in screened group vs. 100 in control group; relative risk 1.18,95% CI 0.82-1.71) 2. The UKCTOCS trial, the largest screening trial with 202,638 women followed for a median of 16.3 years, similarly showed no significant mortality reduction with either multimodal screening (p=0.580) or ultrasound screening (p=0.360) 3.
Substantial Harms
For every screen-detected ovarian cancer, 2.3 women in the multimodal screening group and 10 women in the ultrasound-only group underwent unnecessary surgery for benign conditions 3. In the PLCO trial, approximately 10% of screened women had false-positive results, with one-third undergoing oophorectomy. The surgery-to-cancer detection ratio was 20:1, with 21 major complications per 100 surgical procedures performed for false-positive results 2.
Current Guidelines
The 2025 ACR Appropriateness Criteria explicitly state there is insufficient published evidence to recommend ovarian cancer screening in average-risk patients, as randomized controlled trials have not demonstrated a mortality benefit 1. The USPSTF gives this a D recommendation (recommends against screening), concluding with moderate certainty that harms outweigh benefits 2.
High-Risk Women: Limited Screening May Be Considered
For women at high genetic risk (BRCA1/2 mutations conferring up to 39% lifetime ovarian cancer risk), screening with pelvic ultrasound may be appropriate, though evidence remains limited 1.
Who Qualifies as High-Risk
- BRCA1 or BRCA2 mutation carriers (highest risk)
- Strong family history (first-degree relative with premenopausal ovarian cancer)
- Other hereditary cancer syndromes
Screening Approach for High-Risk Women
When screening is pursued in high-risk women, the combination of:
- Transvaginal ultrasonography
- CA-125 testing
- Physical examination
may be offered every 3-4 months 4, though no randomized trials have demonstrated survival benefit even in this population 1.
Critical Caveat
Risk-reducing salpingo-oophorectomy (RRSO) remains the most effective intervention for women at >4-5% lifetime ovarian cancer risk, as it decreases both ovarian cancer incidence and mortality 4. Screening should not replace surgical prevention in appropriate candidates.
Performance Characteristics
The multimodal screening approach (CA-125 with risk algorithm plus transvaginal ultrasound) demonstrated:
- Sensitivity: 83.8% (95% CI 78.7-88.1)
- Specificity: 99.8% (95% CI 99.8-99.9)
- Positive predictive value: only 28.8% (95% CI 25.5-32.2)
Ultrasound-only screening performed worse:
- Sensitivity: 72.2% (95% CI 65.9-78.0)
- Specificity: 99.5% (95% CI 99.5-99.5)
- Positive predictive value: only 9.1% (95% CI 7.8-10.5) 3
These poor positive predictive values explain the high false-positive surgery rates.
Common Pitfalls to Avoid
Do not use "early stage detection" as a surrogate for mortality benefit: UKCTOCS showed 39.2% higher Stage I/II detection with multimodal screening, yet this did not translate to mortality reduction 3. Stage shift alone is insufficient justification for screening.
Do not confuse diagnostic evaluation with screening: Women with symptoms (bloating, pelvic pain, urinary symptoms) require diagnostic workup, not screening. However, 95% of women report at least one of these nonspecific symptoms annually, making symptom-based screening impractical 2.
Do not screen based solely on family history without genetic assessment: Women with concerning family history should be referred for genetic counseling and BRCA testing first, not empirically screened 2.
Bimanual pelvic examination is ineffective for ovarian cancer screening: The PLCO trial discontinued bimanual examination as a screening strategy because no cases were detected solely by this method 2.
Emerging Technologies
Novel approaches including multivariate index assays, artificial intelligence, radiomics, and liquid biopsy show promise but require large-scale validation before clinical adoption 5, 6. No alternative screening test is currently approved or recommended for routine use.